Accelr8 Presents Two Studies at ASM 2012 and Receives Acceptance to Present a New Blood Study
22 Junio 2012 - 5:00AM
Business Wire
Accelr8 Technology Corporation (NYSE MKT: AXK) announced results
of two studies that it presented at the 112th annual General
Meeting of the American Society for Microbiology (www.asm.org).
The first study used the company’s BACcel™ rapid automated
diagnostic system with positive blood cultures to detect a major,
complex multi-drug resistance expression type known as “ESBL.” The
system’s 3-hour results showed the benefits of the platform
decreasing time to result by 1-2 days over the best standard method
while maintaining 100% sensitivity and 94% specificity. ESBL
resistance has spread globally with hundreds of molecular variants.
Early ESBL spread occurred in hospitals, but is now reaching into
community-acquired infections. These resistance types are difficult
to detect and severely reduce treatment options in the largest
family of Gram-negative pathogens.
The second study reported performance of the company’s rapid,
fully automated specimen preparation technology. It showed that in
10 minutes or less, the BAC-Xtrax™ gel electrofiltration system
concentrates live bacteria and substantially clears the sample from
complex interference. The BAC-Xtrax™ concentrated live cells more
than 100-fold from the original samples, exceeding the best
standard method by more than 10 times. It recovered essentially all
of the organisms in the samples, with variation comparable to that
of the quantitative culturing reference method.
Separately, Accelr8 also received notice of acceptance to
present results at ICAAC 2012 for a new study entitled “Same-Day
Blood Culture with Digital Microscopy.” The study examines
alternatives for shortening the currently typical overnight delay
for cultures before beginning analysis of blood-borne
infections.
About Accelr8
Accelr8 Technology Corporation (www.accelr8.com) is a developer
of innovative materials and instrumentation for advanced
applications in medical instrumentation, basic research, drug
discovery, and bio-detection. Accelr8 is developing a rapid
analytical platform for infectious pathogens, the BACcel™ system,
based on its innovative assay processing and detection
technologies. In addition, Accelr8 licenses certain of its
proprietary technology for use in applications outside of Accelr8’s
own products.
Certain statements in this news release may
be “forward-looking statements” within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Statements regarding
future prospects and developments are based upon current
expectations and involve certain risks and uncertainties that could
cause actual results and developments to differ materially from the
forward-looking statement, including those detailed in the
company's filings with the Securities and Exchange Commission.
Accelr8 does not undertake an obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information or future events.
Accelr8 (AMEX:AXK)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Accelr8 (AMEX:AXK)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
Real-Time news about Accelerate Diagnostics, Inc. (American Stock Exchange): 0 recent articles
Más de Accelr8 Technology Corporation Artículos de Noticias